BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
Human Growth Hormone, Vosoritide Injection
Turner Syndrome, Noonan Syndrome, Short Stature Homeobox- Containing Gene Shox Deficiency
Phase II
Recruiting
A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Oct 30, 2024
Vosoritide
Hypochondroplasia
Phase III
Active Not Recruiting
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Jun 07, 2024
―
Valoctocogene Roxaparvovec
Hemophilia A
Phase III
Active Not Recruiting
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
Jan 16, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does BioMarin Pharmaceutical (BM8) have in its pipeline
BM8 is currently developing the following drugs: Inz-701, Vosoritide, Vosoritide. These drug candidates are in various stages of clinical development as the company works toward FDA approval.